Introduction
============

The number of patients with end-stage renal disease (ESRD) dependent on intermittent hemodialysis has exceeded 320,000 and is still increasing in Japan.^[@R1])^ The development of hemodialysis has improved the long-term survival of patients and has increased availability of dialysis, including to older or diabetic individuals who have poor autogenous vessels.^[@R2])^ The need for secondary, tertiary, or even more vascular access is thus growing. Because autogenous arteriovenous fistulas (AVFs) offer better patency rates with fewer complications and lower mortality rates compared with other options for vascular access, including prosthetic grafts (arteriovenous graft; AVG) or catheters,^[@R2]--[@R4])^ a structured approach to optimize the use of autogenous veins in the upper limbs seems imperative for vascular access.^[@R5])^

Transposed brachiobasilic arteriovenous fistula (TBBAVF) was introduced by Dagher in 1986^[@R6])^ and has shown many favorable results in terms of patency and access-related complication.^[@R7]--[@R9])^ Anatomically, the basilic vein is usually longer and has thicker wall than the cephalic vein.^[@R10],[@R11])^ This vessel is also relatively preserved from repeated cannulation of blood draws and intravenous catheter. Despite those theoretical advantages, the basilic vein needs to be translocated for cannulation in chronic hemodialysis therapy. On the other hand, AVF using the transposed basilic vein involves various unsolved or controversial issues regarding indication of staged operation, means of elevation, and timing of creation compared with the fistula using a prosthetic graft.^[@R12]--[@R14])^ Moreover, the transposed fistula has some limitations, including complex procedures, longer maturation time for cannulation and non-enthusiastic recommendation in the Japanese guideline for vascular access,^[@R15])^ which might be causes of the lower prevalent at this point in Japan.

The purpose of this study was to address the issues and controversies surrounding TBBAVF and to discuss its potential role for creation and management of vascular access in Japan.

Use of Vascular Access in Japan
===============================

Annual reports from the United States Renal Data System indicated that the number of treated cases of ESRD in Japan in 2014 was 2,505 per million population (3,287 in men and 1,764 in women), making Japan the country with the second highest prevalence.^[@R16])^ For the record, 96.9% of the Japanese dialysis patients selected hemodialysis as a renal replacement therapy, and only approximately 1,500 renal transplantations are performed annually in Japan.^[@R17])^ The mean survival time of Japanese patients after first-ever hemodialysis is 7.3 years, one of the longest in the world.^[@R1])^ Patients with hemodialysis for more than 10 years account for up to 27.8%, and those with long-term hemodialysis are increasing in number, whereas patients with hemodialysis therapy for 5 years or less account for 47.3% of all the hemodialysis population in Japan.^[@R1])^ At the same time, Japanese hemodialysis patients tend to be older and show a stronger association with diabetes, with the average age of 67.2 years and 37.6% of all hemodialysis with diabetes in 2013.^[@R1])^ AVFs are recognized as a better choice for most hemodialysis patients compared with prosthetic implants such as artificial grafts or central venous catheters (CVCs)^[@R4],[@R18])^ because of complications including infection. Therefore, it is worthy of special mention that Japan showed one of the highest rates of AVF use, in more than 90% of hemodialysis patients, according to the Dialysis Outcomes and Practice Patterns Study from the United States.^[@R19])^ Moreover, along with 9% using artificial graft (AVG), the most notable feature was that less than 1% of the patients were undergoing dialysis with CVC in Japan.^[@R19])^ In addition, among incident first-ever hemodialysis patients, AVF use in Japan is also one of the highest rates in the world, with more than 80% using AVF, comparing 65% in Germany and 38% in the United States.^[@R19])^ These results indicate that continuing efforts by Japan dialysis units are avoiding CVC and optimizing vascular access use from first-ever hemodialysis treatment.^[@R20])^ Despite such efforts, development of AVF as a vascular access still faces a hostile situation in Japan, because a substantial proportion of patients lack good superficial vessels, and such patients are increasing along with increases in elderly and diabetes patients.^[@R21])^

Anatomy of the Basilic Vein
===========================

The basilic vein, originating on the medial side of dorsal venous network, runs along the medial aspect of the forearm and connects with the medial cubical vein in the elbow. This vessel runs up the ulnar aspect of the upper arm and pierces into the brachial fascia to connect with the brachial vein to form the axillary vein. In the upper arm, the basilic vein runs along with the medial antebrachial cutaneous nerve. However, several variations in basilic vein anatomy exist. Anaya-Ayala et al. described three types of brachial--basilic vein connections based on ultrasound scanning: type 1 (66%), basilic--brachial junction at the axillary level; type 2 (17%), basilic--brachial junction at the mid or lower portion of the upper arm with the duplication of the brachial vein; and type 3 (17%), basilic--brachial junction at the mid or lower portion of the upper arm with no duplication of the brachial vein.^[@R22])^ Hyland analyzed basilic--brachial vein using preoperative venography for vascular access and reported early basilic--brachial vein confluence in 44% and multi-junctions of basilic--brachial vein in 7%.^[@R23])^ Simply put, more than one-third of the upper limbs show a low junction of basilic--brachial confluence.

Preoperative Evaluation
=======================

Preoperative imaging by ultrasound improves the outcomes of AVF creation.^[@R24],[@R25])^ Such evaluations should include the veins and arteries throughout the forearm and upper arm, with assessment of their diameter and quality. Although vein diameter over 2.5 mm has been recommended for AVF maturation,^[@R26])^ some authors favor vein diameter over 3.0 mm for TBBAVF^[@R27],[@R28])^ because the basilic vein needs to be mobilized with discission of all tributaries, which results in increasing peripheral resistance. The diameter of the brachial artery should be over 2.0 mm without a reduced pressure gradient or Doppler waveform that would suggest arterial inflow stenosis. These assessments would help identify anatomical variations of the arteries and veins.

Surgical Technique
==================

Although Hossny classified the techniques in creating brachiobasilic AVF into three types (one-stage transposition, one-stage elevation, and two-stage elevation),^[@R29])^ these procedures accepted regarding creating TBBAVF along with various technical modifications; one-stage transposition, one-stage elevation, two-stage transposition, or two-stage elevation procedures ([**Fig. 1**](#figure1){ref-type="fig"}).

![Fig. 1 Schema of types of TBBAVF. One-stage procedure comprises arteriovenous anastomosis and anterior and superficial relocation of the basilic vein in one operation. Two-stage procedure is a creation of arteriovenous fistula followed by relocation of the basilic vein at different times. Transposition is a relocation with tunneling using tunneler device and elevation indicates moving superficially without tunneling. (**A**) one-stage transposition; (**B**) one-stage elevation; (**C**) two-stage transposition; (**D**) two-stage elevation.](avd-11-2-ra.18-00009-figure01){#figure1}

One-stage procedure: This procedure is an original method for TBBAVF, comprising arteriovenous anastomosis and anterior and superficial relocation of the basilic vein.^[@R6])^ Under an interscalene nerve block with or without intravenous sedation, the basilic vein is exposed from the ulnar aspect of the forearm to the axilla with a continuous or interrupted longitudinal incision. All branches of the basilic vein should be ligated and mobilized proximally to the confluence with the brachial vein. The axillary vein at the confluence should also be mobilized to facilitate the smooth transposition of the basilic vein. The antebrachial subcutaneous nerve, running along with the basilic vein in the upper arm, is carefully spared. The basilic vein is gently distended with heparinized saline to eliminate distortion. The brachial artery is then explored at the elbow. The mobilized basilic vein is transposed to the anterior arm inside a subcutaneous pocket by direct dissection (transposition). Korkut and Kosem recently described transposition of mobilized basilic vein with the use of tunneling device under separate skin incision.^[@R30])^ Although transposition is a common way of superficial relocation, a few groups prefer primary elevation for TBBAVF, simply comprising mobilization of basilic vein superficially (elevation).^[@R31],[@R32])^ In their opinion, elevation may reduce the risk of kinking or twisting of the fistula. Special attention should be paid to ensure that the vein shows a smooth curve near the axilla without twisting. After systemic anticoagulation with heparin sulfate, a vascular clamp is made with a 5 mm arteriotomy in the brachial artery and an end-to-side anastomosis is constructed using a 6-0 or 7-0 polypropylene suture. The course of the vein should be examined closely, and the presence of a thrill is a key to creating successful fistula ([**Fig. 2**](#figure2){ref-type="fig"}).

![Fig. 2 Illustration of surgical procedure of one-stage transposition. (**A**) preoperative marking; (**B**) distention of the basilic vein with heparinized saline to eliminate distortion; (**C**) tunneling of mobilized basilic vein; (**D**) completion of anastomosis between the transposed basilic vein and the brachial artery.](avd-11-2-ra.18-00009-figure02){#figure2}

Two-stage procedure: The first stage of this procedure is simply the creation of the AVF, followed by the second stage of elevation or transposition.^[@R33],[@R34])^ The first stage includes an end-to-side anastomosis between the basilic vein and the brachial artery in the elbow. Several weeks later, at the time of the basilic vein maturation, the basilic vein is mobilized from the previous anastomosis site to the confluence with the brachial vein through continuous or interrupt longitudinal incision. The two-stage method may facilitate placement of pressure on smaller ramifications and reduce the risk of surgical flaw at the time of mobilization. With the creation of a pocket in the subcutaneous tissue, the basilic vein is relocated superficially and anterolaterally for "elevation,"^[@R35])^ or the fistula vein is transected, then routed via the superficial tunnel anterolaterally and re-anastomosed, representing "transposition" instead of simple elevation. Although elevation and transposition are confused in some reports, transposition method seems to be more prevalent because denuded area can be reduced in the second stage. Wang et al. recently compared two-stage elevation with two-stage transposition and found that two-stage elevation is a reliable approach because of better primary patency and reduced need for salvage interventions to the fistulas.^[@R36])^ The interval between the first and second operations is varied from 3 to 8 weeks depending on the maturation criteria of the basilic vein.

Other techniques: Several surgical modifications have been described, usually comprising reduced tissue dissection to avoid skin complications.^[@R37]--[@R40])^ Using endoscopic vein-harvesting system with sealing and division of the branches of the basilic vein, several small incision techniques offer comparable results with those of the regular open method.

Criteria of Maturation
======================

Without standard criteria for fistula maturation, there are no specific criteria of maturation for TBBAVF. In Japan, early cannulation tends to be performed with a minimal access flow rate of 160 mL/min for radial--cephalic AVF, compared with 200 mL/min in Europe and 300 mL/min in the United States. According to the KDOQI 2006 guidelines, functional access can be defined for fistula diameter \>6 mm, access flow \>600 mL/min and the depth \<6 mm.^[@R18])^ Arroyo et al. described the following criteria for maturation in TBBAVF: fistula vein diameter \>6 mm, estimated access flow \>400 mL/min without stenosis.^[@R41])^ Lioupis' criteria were fistula vein diameter \>3.5 mm and access flow \>600 mL/min.^[@R42])^ Because Voormolen et al. identified immature AVF as providing insufficient access flow at 6 weeks after creation^[@R43])^ and the vascular access guideline in Japan showed below 200 mL/min of access flow as insufficient flow, more than 300 mL/min of access flow 6 weeks after creation would be minimum for TBBAVF. Rao et al. reported a high failure rate for maturation in TBBAVF, up to 38%.^[@R44])^ However, other reports have usually described lower maturation around 10--20%. Hakaim et al. compared radiocephalic, brachiocephalic, and TBBAVFs, reporting superior maturation of TBBAVF in diabetic patients.^[@R45])^

TBBAVF vs. AVG
==============

Several reports have compared TBBAVF with prosthetic vascular access. As fistulas using prosthetic graft (AVG) show wide variation, including brachial--antecubital forearm loop or brachial--axial straight with several prosthetic graft materials, methods should be tested one by one when comparing between TBBAVF and AVG in each manuscript. [**Table 1**](#table1){ref-type="table"} summarizes the main outcomes reported in various studies.^[@R42],[@R46]--[@R62])^ Chemla and Morsy found that TBBAVF offered a better patency rate with greater cost-effectiveness compared with brachio-axillary AVG.^[@R53])^ Chue et al. studied 122 Asian patients and reported that TBBAVF provided superior patency and required fewer salvage interventions compared with forearm AVG.^[@R62])^ However, recent studies showed comparable patency between AVG and TBBAVF and have favored the use of prosthetic grafts in specific groups like elderly patients, because of the short cannulation period.^[@R42],[@R55],[@R61])^ Overall, utilization of TBBAVF is associated with reduced risk of access failure, whereas AVG represents the preferred option for elderly patients.^[@R63])^

###### Table 1 List of studies compared TBB­AVF with AVG

  First author     Year   Study                             Number of patients   Patency at 1 year (primary/secondary)   Patency at 2 years (primary/secondary)   Type of prosthesis                  Main complications                                        Comment
  ---------------- ------ ------------------------ -------- -------------------- --------------------------------------- ---------------------------------------- ----------------------------------- --------------------------------------------------------- ----------------------------------------------------
  Coburn           1994   Retrospective            TBBAVF   59                   90\*                                    86\*                                                                         Infection 3.4%, bleeding 6.8%                             
                                                   AVG      47                   70/87                                   49/64                                    PTFE                                Infection 16.1%, bleeding 1.6%                            
  Matsuura         1998   Retrospective            TBBAVF   30                                                           70                                                                           Infection 0%                                              
                                                   AVG      67                                                           46                                       Brachio-axillary, PTFE              Infection 10%                                             
  Gibson           2001   Retrospective            TBBAVF   181                                                          27.7/61.5                                                                                                                              Benefit for women and patients with access failure
                                                   AVG      64                                                           24.6/39.8                                                                                                                              
  Oliver           2001   Retrospective            TBBAVF   59                   /64                                                                                                                  Infection 2%, poor maturation 6%, arm swelling 3%         
                                                   AVG      82                   /62                                                                              PTFE                                Infection 13%, poor maturation 1%, arm swelling 6%        
  Weale            2007   Retrospective            TBBAVF   71                   45.3/53.6                               40.0/50.9                                                                    Infection 0%                                              
                                                   AVG      114                  56.4\*                                  43.2\*                                   Brachio-axillary                    Infection 6.2%                                            
  Kakkos           2008   Controlled comparative   TBBAVF   76                   46/87 (primary assist, 82%)                                                                                          Infection 0%, bleeding 9.8%, venous hypertension 15%      
                                                   AVG      41                   50/88 (primary assist, 70%)                                                      Brachio-axillary, Vectra            Infection 6.6%, bleeding 2.6%, venous hypertension 1.3%   
  Keuter           2008   Randomized               TBBAVF   52                   46/89 (primary assist, 87%)                                                                                          Incidence rate of complications: 1.6 per patient-year     
                                                   AVG      53                   22/85 (primary assist, 71%)                                                      Forearm loop, PTFE                  Incidence rate of complications: 2.7 per patient-year     
  Chemla           2008   Retrospective            TBBAVF   34                   73/93                                   69/85                                                                                                                                  TBBAVF: cost-effective
                                                   AVG      42                   61/70                                   54/62                                    Brachio-axillary, PTFE (Intering)                                                             
  Pflederer        2008   Retrospective            TBBAVF   161                  58/97                                   44/97                                                                        Infection rate: 0.07 per patient-year                     
                                                   AVG      285                  18/66                                   5/54                                     Loop, straight                      Infection rate: 0.23 per patient-year                     
  Torina           2008   Retrospective            TBBAVF   42                   45/74 (primary assist, 74%)\*\*                                                                                                                                                
                                                   AVG      94                   50/78 (primary assist, 63%)                                                                                                                                                    
  Maya             2009   Prospective              TBBAVF   67                                                           /55                                                                          Primary access failure: 15%                               
                                                   AVG      289                                                          /45                                                                          Primary access failure: 18%                               
  Woo              2009   Retrospective            TBBAVF   119                  65\*                                                                                                                 Infection 1.6%, bleeding 3.7%, steal 3.2%                 
                                                   AVG      168                  48\*                                                                             Upper arm, PTFE                     Infection 7.9%, bleeding 1.8%, steal 4.9%                 
  Sala Almonacil   2011   Retrospective            TBBAVF   36                   50.4/50.4                               45.8/45.8                                                                    Infection 0%, access problem 13.8%                        
                                                   AVG      40                   64.3/67.7                               46.2/54.2                                Brachio-axillary, PTFE              Infection 10%, access problem 5%                          
  Lioupis          2011   Retrospective            TBBAVF   45                                                           51\*\*\*                                                                                                                               Access intervention: higher in AVG group
                                                   AVG      48                                                           55\*\*\*                                 Brachio-axillary, PTFE (Flixene)                                                              
  Morosetti        2011   Retrospective            TBBAVF   30                   61/76                                   60/66                                                                                                                                  
                                                   AVG      27                   32/52                                   21/34                                    Polyester Omniflow                                                                            
  Basel            2011   Retrospective            TBBAVF                                                                67                                                                                                                                     
                                                   AVG                                                                   32                                                                                                                                     
  Davoudi          2013   Randomized               TBBAVF   30                   76.3                                                                                                                 Similar thrombosis or infection rate                      
                                                   AVG      30                   70                                                                               Brachio-axillary                                                                              
  Chue             2016   Retrospective            TBBAVF                        73.2/71.8                                                                                                                                                                      
                                                   AVG                           34.1/54.3                                                                        Forearm loop, PTFE                                                                            

\*: secondary not described; \*\*: two-stage procedure; \*\*\*: secondary patency at 18 months

One-Stage vs. Two-Stage Approach
================================

The choice between one- and two-stage approaches has been a subject of focus in creating TBBAVF. To date, two randomized reports have compared one- and two-stage procedures, showing higher maturation and better 1 year patency in the two-stage procedure.^[@R64],[@R65])^ However, both studies have critical limitations, including small sample size (n=16) in the study by Kakkos et al.^[@R65])^ and short follow-up period in El Mallah's study,^[@R64])^ with considerable disparity in maturation rate and patency compared with their former report.^[@R65],[@R66])^ Data on the features of one- or two-stage procedures of TBBAVF have been accumulated from several retrospective studies.^[@R67])^ Mixed opinions have been reported regarding functional patency rate, with some studies describing better patency rates under the two-stage approach and some showing comparable patency rates in both groups.^[@R66],[@R68],[@R69])^ Vrakas et al. reported better 2 year primary and secondary patency rates of 75% and 77% for two-stage approach, respectively, compared with those of 53% and 57% for one-stage approach.^[@R70])^ Ozcan et al. found that those two approaches offered similar patency and a higher complication rate in one-stage approach including thrombosis and hematoma.^[@R68])^ Bashar et al. conducted a systematic review and meta-analysis for eight manuscripts covering 859 fistulas, concluding that the differences between one- and two-stage procedures were not statistically significant in terms of overall maturation rate or postoperative complication, with comparable patency rates.^[@R71])^ However, recent reports have indicated better patency with the two-step method, and Mauro et al. found that transecting the basilic vein at the anastomosis and tunneling it superficially led to fewer complications and easier cannulation than elevating the basilic artery in the two-stage procedure.^[@R72])^ In general, reports overall showed that the rate of fistula maturation was higher, but the time to cannulation was longer in the two-stage procedure.^[@R65],[@R68],[@R69])^ Even so, an assessment by Ghaffarian et al. revealed that two-stage procedure was cost-effective with higher patency and lower rates of failure.^[@R73])^ [**Table 2**](#table2){ref-type="table"} showed the summary of main studies so far.^[@R29],[@R64]--[@R66],[@R68]--[@R70],[@R73]--[@R75])^

###### Table 2 List of main studies compared between one-stage and two-stage procedures in TBB­AVF

  Authors                              Year                                                Study type      Number                               Maturation rate (%)   Secondary patency at 2 years   Complication         Recommendation                                                    
  ------------------------------------ --------------------------------------------------- --------------- ------------------------------------ --------------------- ------------------------------ -------------------- ---------------- ------------------------------------------------ -----------
  El Mallah                            1998                                                Randomized      One stage 20                         60                    90                                                                                                                    Two stage
  Two stage 20                                                                                                                                                                                                                                                                              
  Hossny                               2003                                                Retrospective   One-stage transposition 40                                                                Transposition 82.8   Elevation 68.4   Hematoma: 26.3% in elevation group               
  One-stage elevation 20               Elevation 70                                                                                                                                                                                                                                         
  Two-stage elevation 20                                                                                                                                                                                                                                                                    
  Kakkos                               2010                                                Retrospective   One-stage transposition 76           85\*\*                82\*\*                                                               Complications: higher in one-stage method        Two stage
  Two-stage transposition 98 (72)\*    10 in two-stage group did not attain second stage                                                                                                                                                                                                    
  Reynolds                             2011                                                Retrospective   One-stage transposition 60           77.1                  90.9                           41                   94               30 days complications: similar in both groups    Two stage
  Two-stage tansposition 30                                                                                                                                                                                                                                                                 
  Syed                                 2012                                                Retrospective                                        79                    82                             81                   27                                                                
  Vrakas                               2013                                                Retrospective   One-stage transposition 65           55                    58                             57                   77               Complications: similar in both groups            Two stage
  Two-stage elevation 84                                                                                                                                                                                                                                                                    
  Ozcan                                2013                                                Retrospective   One stage 47 (basilic vein \>3 mm)   66                    77                             98                   98               Complications: higher in one-stage method        Two stage
  Two stage 59 (basilic vein \<3 mm)                                                                                                                                                                                                                                                        
  Robertson                            2013                                                Retrospective   One stage 29                         76                    84                             86.2\*\*\*           91.6\*\*\*                                                        One stage
  Two stage 44                                                                                                                                                                                                                                                                              
  Agarwal                              2014                                                Retrospective   One stage 61                         90                    75                             75                   71               Required interventions: similar in both groups   
  Two stage 83                                                                                                                                                                                                                                                                              
  Kakkos                               2015                                                Randomized      One-stage transposition 9            33                    100                            44                   86                                                                Two stage
  Two-stage transposition 7                                                                                                                                                                                                                                                                 
  Ghaffarian                           2017                                                Retrospective   One stage 57                                                                              44                   73               Complications: similar in both groups            Two stage
  Two stage 74                         Two stage was durable and cost-effective                                                                                                                                                                                                             

\*: 72 out of 98 underwent a second-stage operation; \*\*: including lost or refuse patients; \*\*\*: secondary patency at 6 months

Complications
=============

No specific postoperative complications are associated with TBBAVF.^[@R14])^ However, the incidence of complications such as arm edema and access-related bleeding seems higher than with other vascular access, attributable to the extensive surgical mobilization and cannulation in the early period. Woo et al. reported that the incidence of infectious complications was much lower for TBBAVF, at around 2%, compared with 8% with AVG.^[@R76])^ Beaulieu et al. noted that the most common complication of TBBAVF in the long-term period was stenosis, and the site of stenosis was commonly the confluence of transposition of the basilic vein to the brachial vein.^[@R77])^ Intervention for such stenosis appears effective, although repeated intervention may be necessary.

TBBAVF in Japan
===============

Japan has shown one of the highest AVF use, in more than 90% of the hemodialysis patients. Radiocephalic AVF followed by brachiocephalic AVF is usually created when the superficial cephalic vein is available. AVG is usually the next option, and TBBAVF is not at all common in Japan. Because the KDOQI Clinical Practice Guidelines for Vascular Access place TBBAVF prior to AVG in the order for fistula placement and suitable basilic vein are left unused in many Japanese patients, creation of TBBAVF should be an option before AVG for many Japanese patients. However, considering the low maturation rate and longer time required for cannulation, TBBAVF may be a tertiary or subsequent fistula even in Japan. We found that TBBAVF might achieve maturation for cannulation when the basilic vein is identified as ≥3 mm in diameter preoperatively. The long time until cannulation may cost patients with CVC catheter for a couple of months. Therefore, a one-step approach of TBBAVF rather than a two-step approach may be favorable to reduce catheter time in Japan, although further study is clearly needed. We reported some of TBBAVF with one-step procedure can be used 2 weeks after creation when the fistulas showed good thrill,^[@R78])^ which would be one solution for reduced time for cannulation. One opinion is that the forearm loop AVG is a better option than TBBAVF because the stenosis of confluent site at the basilic vein in TBBAVF ruins the choice of forearm loop AVG. However, it is important to remember that forearm loop AVG shows critical complications such as infection. Even if forearm loop AVG does represent a useful alternative to TBBAVF, the basilic vein should be carefully preserved for a backup fistula.

Conclusion
==========

TBBAVF offers a valuable autogenous vascular access and represents a good alternative after radial--cephalic and brachial--cephalic configuration. Issues remain regarding TBBAVF, including selection of a one- or two-stage approach, superiority over new artificial graft, and indications for hostile vascular access patients such as those with older age or diabetes, but TBBAVF represents the essential option for a structured approach to optimize autogenous veins for vascular access.
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